Form 4: Corcept Therapeutics Director Acquires Stock Options

Corcept Therapeutics Director Daniel N. Swisher Jr. acquired 12,500 stock options on May 21, 2026, as detailed in a recent SEC Form 4 filing.

Summary

• Daniel N. Swisher Jr., a Director at Corcept Therapeutics Inc., was granted 12,500 stock options on May 21, 2026.
• These options have an exercise price of $59.69 and are exercisable over a one-year period starting May 21, 2026, vesting monthly, contingent upon continued service.
• The underlying securities are 12,500 shares of Corcept Therapeutics' common stock.
• The filing indicates that Swisher Jr. is a director and not a 10% owner or officer.
• The transaction was executed under a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director under a pre-arranged plan, with no immediate financial transaction or significant new information about the company's performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The 10b5-1 plan suggests a pre-determined and structured approach to stock transactions, potentially reducing concerns about insider trading.
• The options are exercisable over a year, indicating a phased vesting tied to continued service, which can incentivize long-term commitment.

Negatives

• The filing only reports the acquisition of options, not the exercise or sale of shares, so immediate financial benefit is not yet realized.
• The exercise price of $59.69 implies that the stock price needs to appreciate significantly for these options to be profitable.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance.
• Continued service is a condition for vesting, meaning any departure from the company before full vesting would result in forfeiture of unvested options.

Future Outlook

The future outlook for the stock options is dependent on Corcept Therapeutics' stock performance and the continued service of Daniel N. Swisher Jr. The options are exercisable over a one-year period starting May 21, 2026, and expire on May 21, 2036.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and pharmaceutical sectors, often used as a long-term incentive to align management's interests with those of shareholders. This filing for Corcept Therapeutics (CORT) falls within this typical industry behavior.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive alignment of interests, potentially leading to increased focus on long-term value creation. However, the actual impact depends on the company's future stock performance.
• Employees: While not directly impacting employees, such grants to senior leadership can reflect a broader compensation philosophy within the company.
• Management: The options provide a potential financial incentive for continued service and performance.

Next Steps

• Daniel N. Swisher Jr. will vest in the stock options monthly over a one-year period, subject to continued service.
• The options can be exercised anytime between their vesting dates and the expiration date of May 21, 2036.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Director, SEC Filing, Equity